T 89

Drug Profile

T 89

Alternative Names: Cardiotonic Pills; Compound Danshen Dripping Pills; Danshen Plus; Dantonic Capsule; Salvtonic; T89; Tasly Danshen Plus Capsule

Latest Information Update: 23 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tianjin Tasly Pharmaceutical
  • Developer Tasly Pharmaceutical Group; Tasly Pharmaceuticals, Inc.
  • Class Herbal medicines; Ischaemic heart disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Diabetic retinopathy

Most Recent Events

  • 01 Dec 2016 Tasly Pharmaceuticals completes a phase III trial in Angina pectoris in USA, Belarus, Georgia, Mexico, Ukraine, Russia and Canada (PO) (NCT01659580)
  • 01 May 2013 Phase-III clinical trials in Diabetic retinopathy in China (PO) (NCT02388984)
  • 28 Feb 2013 Tasly Pharmaceuticals completes a phase I/II trial in Healthy Japanese volunteers in USA (NCT01679028)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top